Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Michael NorthendWilliam WilsonWendy OsborneChristopher Paul FoxAndrew John DaviesDima El-SharkawiElizabeth H PhillipsHau Wui SimShalal SadullahNimish ShahYing Ying PengIman QureshiJuanah AddadaRocio Figueroa MoraNeil PhillipsAndrea KuhnlElizabeth DaviesDavid WrenchPamela McKayIndrani KarphaAnna CowleyRichard KarimSarah ChallenorVikram SinghCathy BurtonRebecca AuerChris WilliamsJoel CunninghamAngus BroomAnita ArasaretnamClaire RoddieTobias MenneWilliam TownsendPublished in: Blood advances (2022)